Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Emerging
Primary summary from verified readiness
- Confidence
- 69% · fresh
- Computed at
- 2026-07-21T07:33:27.723541+00:00
- Claimed
- 42
- Reported
- 37
- Verified
- 29
- Gap
- +13
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-07-21
Track; not yet
- Why
- Genuinely competitive Phase 2 efficacy (11.5% weight loss at 36 weeks, still trending down) in the single hottest 2026 pharma category, but still Phase 2-only outside China, GI tolerability unresolved, and no announced global registrational trial start -- too early to score as near-market.
- Next
- Re-open at global (ex-China) Phase 3 initiation or topline readout, or at first FDA/EMA filing, whichever comes first
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 5
- Tier 1
- 0
- Tier 2
- 5
- Tier 3
- 0
- Supports
- 2
- Contradicts
- 1
- Context
- 2
- Latest observed
- 2026-07-01
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-21 Reading moved from emerging to emerging.